The University of Chicago Header Logo

Connection

Ardaman Shergill to Aged

This is a "connection" page, showing publications Ardaman Shergill has written about Aged.
Connection Strength

0.384
  1. Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3453-3461.
    View in: PubMed
    Score: 0.064
  2. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 05; 8:e2300531.
    View in: PubMed
    Score: 0.057
  3. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 06 01; 238(6):1013-1020.
    View in: PubMed
    Score: 0.056
  4. Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026 Sep 01; 336(9):746-754.
    View in: PubMed
    Score: 0.017
  5. Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. J Surg Oncol. 2026 Jun; 133(8):1016-1022.
    View in: PubMed
    Score: 0.016
  6. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
    View in: PubMed
    Score: 0.016
  7. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precis Oncol. 2026 Feb; 10:e2500741.
    View in: PubMed
    Score: 0.016
  8. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
    View in: PubMed
    Score: 0.016
  9. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
    View in: PubMed
    Score: 0.016
  10. Utilizing Patient Input in Rectal Cancer Trial Design. J Natl Cancer Inst. 2025 Jul 01; 117(7):1421-1428.
    View in: PubMed
    Score: 0.015
  11. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
    View in: PubMed
    Score: 0.015
  12. Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy. JCO Precis Oncol. 2024 09; 8:e2400149.
    View in: PubMed
    Score: 0.015
  13. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 08 20; 42(24):2853-2859.
    View in: PubMed
    Score: 0.014
  14. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 08 20; 42(24):2918-2927.
    View in: PubMed
    Score: 0.014
  15. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.012
  16. Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
    View in: PubMed
    Score: 0.012
  17. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.